TY - JOUR
T1 - Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer
T2 - efficacy and predictive parameters in a large single center cohort
AU - Höfner, Thomas
AU - Vallet, Sonia
AU - Hadaschik, Boris A
AU - Pahernik, Sascha
AU - Duensing, Stefan
AU - Hohenfellner, Markus
AU - Jäger, Dirk
AU - Grüllich, Carsten
N1 - Publisher Copyright:
© 2014, Springer-Verlag Berlin Heidelberg.
PY - 2015/6/22
Y1 - 2015/6/22
N2 - PURPOSE: To report the outcome and course of disease in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel followed by abiraterone acetate in a single center.METHODS: In this retrospective observational study, we reviewed the course of disease of all applicable patients with mCRPC treated with docetaxel followed by abiraterone at our center. We analyzed progression-free survival (PFS) of docetaxel and abiraterone treatments. We further searched for predictive factors for the duration of treatment response.RESULTS: Median PFS between initiation of androgen deprivation therapy and the diagnosis of mCRPC was 32 months. Median PFS on docetaxel treatment was 9 months. Median PFS on abiraterone treatment was 11 months. Patients with higher Gleason scores (GS) (8-10) at initial diagnosis had a significantly longer median PFS on docetaxel as compared to patients with GS 6-7, p = 0.01. We demonstrate a significant correlation between the PFS on docetaxel and PFS on abiraterone in the post-docetaxel setting (Kendall tau r = 0.32, p = 0.019) as well as a significant negative correlation between the PSA nadir under abiraterone treatment and the time to progression under abiraterone (Kendall tau r = -0.43, p = 0.007).CONCLUSIONS: High Gleason score appears to be predictive of duration of response to docetaxel. Interestingly, progression-free survival with abiraterone appears to be correlated with the duration of response with docetaxel, whereas PSA decline and low nadir appear to be predictive of response to abiraterone.
AB - PURPOSE: To report the outcome and course of disease in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel followed by abiraterone acetate in a single center.METHODS: In this retrospective observational study, we reviewed the course of disease of all applicable patients with mCRPC treated with docetaxel followed by abiraterone at our center. We analyzed progression-free survival (PFS) of docetaxel and abiraterone treatments. We further searched for predictive factors for the duration of treatment response.RESULTS: Median PFS between initiation of androgen deprivation therapy and the diagnosis of mCRPC was 32 months. Median PFS on docetaxel treatment was 9 months. Median PFS on abiraterone treatment was 11 months. Patients with higher Gleason scores (GS) (8-10) at initial diagnosis had a significantly longer median PFS on docetaxel as compared to patients with GS 6-7, p = 0.01. We demonstrate a significant correlation between the PFS on docetaxel and PFS on abiraterone in the post-docetaxel setting (Kendall tau r = 0.32, p = 0.019) as well as a significant negative correlation between the PSA nadir under abiraterone treatment and the time to progression under abiraterone (Kendall tau r = -0.43, p = 0.007).CONCLUSIONS: High Gleason score appears to be predictive of duration of response to docetaxel. Interestingly, progression-free survival with abiraterone appears to be correlated with the duration of response with docetaxel, whereas PSA decline and low nadir appear to be predictive of response to abiraterone.
KW - Aged
KW - Androgen Antagonists/administration & dosage
KW - Androstenes/administration & dosage
KW - Anilides/administration & dosage
KW - Antineoplastic Agents, Hormonal/administration & dosage
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Bone Neoplasms/drug therapy
KW - Buserelin/administration & dosage
KW - Cohort Studies
KW - Disease-Free Survival
KW - Docetaxel
KW - Flutamide/administration & dosage
KW - Humans
KW - Leuprolide/administration & dosage
KW - Liver Neoplasms/drug therapy
KW - Lung Neoplasms/drug therapy
KW - Male
KW - Middle Aged
KW - Nitriles/administration & dosage
KW - Prostatic Neoplasms, Castration-Resistant/drug therapy
KW - Retrospective Studies
KW - Taxoids/administration & dosage
KW - Tosyl Compounds/administration & dosage
KW - Treatment Outcome
KW - Triptorelin Pamoate/administration & dosage
UR - http://www.scopus.com/inward/record.url?scp=84937634196&partnerID=8YFLogxK
U2 - 10.1007/s00345-014-1375-5
DO - 10.1007/s00345-014-1375-5
M3 - Journal article
C2 - 25113804
SN - 0724-4983
VL - 33
SP - 833
EP - 839
JO - World Journal of Urology
JF - World Journal of Urology
IS - 6
ER -